172 related articles for article (PubMed ID: 24375440)
81. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
82. Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Kanesvaran R; Phipps C; Cheng CW; Chan MM; Khoo D; Tan MH
Ann Acad Med Singap; 2010 Jul; 39(7):580-2. PubMed ID: 20697679
[No Abstract] [Full Text] [Related]
83. Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy.
Zhang K; Yan F; Lei X; Wei D; Lu H; Zhu Z; Xiang A; Ye Z; Wang L; Zheng W; Li X; Yuan J; Lu Z; Yuan J
Mol Med Rep; 2018 Jun; 17(6):8203-8211. PubMed ID: 29658587
[TBL] [Abstract][Full Text] [Related]
84. The third analysis of the bicalutamide Early Prostate Cancer programme.
Iversen P;
BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
[No Abstract] [Full Text] [Related]
85. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
86. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Wirth M; Tyrrell C; Wallace M; Delaere KP; Sánchez-Chapado M; Ramon J; Hetherington J; Pina F; Heynes CF; Borchers TM; Morris T; Stone A
Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
[TBL] [Abstract][Full Text] [Related]
87. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
Thomsen FB; Brasso K; Christensen IJ; Johansson JE; Angelsen A; Tammela TL; Iversen P;
Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
[TBL] [Abstract][Full Text] [Related]
88. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
[TBL] [Abstract][Full Text] [Related]
89. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
[TBL] [Abstract][Full Text] [Related]
90. Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
Jia AY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):316-319. PubMed ID: 35569476
[No Abstract] [Full Text] [Related]
91. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.
Haapala K; Hyytinen ER; Roiha M; Laurila M; Rantala I; Helin HJ; Koivisto PA
Lab Invest; 2001 Dec; 81(12):1647-51. PubMed ID: 11742035
[TBL] [Abstract][Full Text] [Related]
92. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
Cheng XH; Black M; Ustiyan V; Le T; Fulford L; Sridharan A; Medvedovic M; Kalinichenko VV; Whitsett JA; Kalin TV
PLoS Genet; 2014 Sep; 10(9):e1004656. PubMed ID: 25254494
[TBL] [Abstract][Full Text] [Related]
93. Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial.
Reddy D; Shah TT; Dudderidge T; McCracken S; Arya M; Dobbs C; Emberton M; Fiorentino F; Day E; Prevost AT; Staffurth J; Sydes M; Winkler M; Ahmed HU
Contemp Clin Trials; 2020 Jun; 93():105999. PubMed ID: 32302790
[TBL] [Abstract][Full Text] [Related]
94. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
Welén K; Rosendal E; Gisslén M; Lenman A; Freyhult E; Fonseca-Rodríguez O; Bremell D; Stranne J; Balkhed ÅÖ; Niward K; Repo J; Robinsson D; Henningsson AJ; Styrke J; Angelin M; Lindquist E; Allard A; Becker M; Rudolfsson S; Buckland R; Carlsson CT; Bjartell A; Nilsson AC; Ahlm C; Connolly AF; Överby AK; Josefsson A
Eur Urol; 2022 Mar; 81(3):285-293. PubMed ID: 34980495
[TBL] [Abstract][Full Text] [Related]
95. Revising the role of the androgen receptor in breast cancer.
Fioretti FM; Sita-Lumsden A; Bevan CL; Brooke GN
J Mol Endocrinol; 2014 Jun; 52(3):R257-65. PubMed ID: 24740738
[TBL] [Abstract][Full Text] [Related]
96. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.
Alonzi R; Padhani AR; Taylor NJ; Collins DJ; D'Arcy JA; Stirling JJ; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):721-7. PubMed ID: 20630668
[TBL] [Abstract][Full Text] [Related]
97. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
[No Abstract] [Full Text] [Related]
98. Sense and Sensibility.
Schattner A
Am J Med; 2021 Dec; 134(12):1570-1571. PubMed ID: 34214460
[No Abstract] [Full Text] [Related]
99. The role of SPDEF in cancer: promoter or suppressor.
Bao KC; Wang FF
Neoplasma; 2022 Dec; 69(6):1270-1276. PubMed ID: 35951453
[TBL] [Abstract][Full Text] [Related]
100. The transcription factor sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (SPDEF) is required for E-cadherin expression in prostate cancer cells.
Pal M; Koul S; Koul HK
J Biol Chem; 2014 Aug; 289(32):22020. PubMed ID: 25108016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
